Literature DB >> 7686182

Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

P Simmonds1, K A Rose, S Graham, S W Chan, F McOmish, B C Dow, E A Follett, P L Yap, H Marsden.   

Abstract

The effect of sequence variability between different types of hepatitis C virus (HCV) on the antigenicity of the NS-4 protein was investigated by epitope mapping and by enzyme-linked immunosorbent assay with branched oligopeptides. Epitope mapping of the region between amino acid residues 1679 and 1768 in the HCV polyprotein revealed two major antigenic regions (1961 to 1708 and 1710 to 1728) that were recognized by antibody elicited upon natural infection of HCV. The antigenic regions were highly variable between variants of HCV, with only 50 to 60% amino acid sequence similarity between types 1, 2, and 3. Although limited serological cross-reactivity between HCV types was detected between peptides, particularly in the first antigenic region of NS-4, type-specific reactivity formed the principal component of the natural humoral immune response to NS-4. Type-specific antibody to particular HCV types was detected in 89% of the samples from anti-HCV-positive blood donors and correlated almost exactly with genotypic analysis of HCV sequences amplified from the samples by polymerase chain reaction. Whereas almost all blood donors appeared to be infected with a single virus type (97%), a higher proportion of samples (40%) from hemophiliacs infected from transfusion of non-heat-inactivated clotting factor contained antibody to two or even all three HCV types, providing evidence that long-term exposure may lead to multiple infection with different variants of HCV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686182      PMCID: PMC265567          DOI: 10.1128/jcm.31.6.1493-1503.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  52 in total

1.  Antibody to superoxide dismutase, autoimmune hepatitis, and antibody tests for hepatitis C virus.

Authors:  Y Ikeda; G Toda; N Hashimoto; K Kurokawa
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

2.  False-positive anti-HCV tests in rheumatoid arthritis.

Authors:  L Theilmann; M Blazek; T Goeser; K Gmelin; B Kommerell; W Fiehn
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

3.  Recombinant immunoblot assay for hepatitis C antibody.

Authors:  S Skidmore
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

Review 4.  Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.

Authors:  Q L Choo; A J Weiner; L R Overby; G Kuo; M Houghton; D W Bradley
Journal:  Br Med Bull       Date:  1990-04       Impact factor: 4.291

5.  There are two major types of hepatitis C virus in Japan.

Authors:  N Enomoto; A Takada; T Nakao; T Date
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

6.  Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.

Authors:  D B Brettler; H J Alter; J L Dienstag; A D Forsberg; P H Levine
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

7.  Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.

Authors:  J I Esteban; A González; J M Hernández; L Viladomiu; C Sánchez; J C López-Talavera; D Lucea; C Martin-Vega; X Vidal; R Esteban
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

8.  Serological markers of posttransfusion hepatitis C viral infection.

Authors:  D S Vallari; B W Jett; H J Alter; L T Mimms; R Holzman; J W Shih
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

9.  Hepatitis C antibody and chronic liver disease in haemophilia.

Authors:  M Makris; F E Preston; D R Triger; J C Underwood; Q L Choo; G Kuo; M Houghton
Journal:  Lancet       Date:  1990-05-12       Impact factor: 79.321

10.  Infectivity of blood seropositive for hepatitis C virus antibodies.

Authors:  C L van der Poel; H W Reesink; W Schaasberg; A Leentvaar-Kuypers; E Bakker; P J Exel-Oehlers; P N Lelie
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

View more
  53 in total

1.  Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy.

Authors:  P Dentico; N Curatolo; R Sacco; M De Luca; A Volpe; C Ranieri; C Genchi; L Petracca; R Buongiorno
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection.

Authors:  D Y Chien; P Arcangel; A Medina-Selby; D Coit; M Baumeister; S Nguyen; C George-Nascimento; A Gyenes; G Kuo; P Valenzuela
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

4.  Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up.

Authors:  G Diodati; P Bonetti; A Tagger; C Casarin; F Noventa; M Ribero; M Fasola; A Ruol; G Realdi
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

5.  Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes.

Authors:  L Stuyver; W van Arnhem; A Wyseur; F Hernandez; E Delaporte; G Maertens
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

6.  Clustering of rare peptide segments in the HCV immunome.

Authors:  Angela Stufano; Giovanni Capone; Barbara Pesetti; Lorenzo Polimeno; Darja Kanduc
Journal:  Self Nonself       Date:  2010-02-03

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Comparative evaluation of two serologic typing methods for hepatitis C virus.

Authors:  A Cerino; A Cividini; M Asti; A Lanza; E Silini; M U Mondelli
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

9.  Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns.

Authors:  J M Pawlotsky; F Roudot-Thoraval; C Pellet; P Aumont; F Darthuy; J Remire; J Duval; D Dhumeaux
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

10.  Analysis of the core and E1 envelope region sequences of a novel variant of hepatitis C virus obtained in Indonesia.

Authors:  H Hotta; H Doi; T Hayashi; M Purwanta; W Soemarto; M Mizokami; K Ohba; M Homma
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.